GSE239844 6 V 9 CRIZOTINIB HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE239844 6 V 9 CRIZOTINIB HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE239844 6 V 9 CRIZOTINIB HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE239844 6 V 9 CRIZOTINIB HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE239844 6 V 9 CRIZOTINIB HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

PWWP domain containing 4

Gene

myosin XVB

Gene

fibronectin type III and ankyrin repeat domains 1

Gene

serine/threonine kinase 31

Gene

solute carrier family 6 member 9

Gene

dynein axonemal light intermediate chain 1

Gene

transient receptor potential cation channel subfamily V member 1

Gene

kelch domain containing 7A

Gene

transmembrane protein 150C

Gene

SRY-box transcription factor 6

  • Gene

    PWWP domain containing 4



  • Gene

    fibronectin type III and ankyrin repeat domains 1


  • Gene

    serine/threonine kinase 31


  • Gene

    solute carrier family 6 member 9


  • Gene

    dynein axonemal light intermediate chain 1


  • Gene

    transient receptor potential cation channel subfamily V member 1


  • Gene

    kelch domain containing 7A


  • Gene

    transmembrane protein 150C


  • Gene

    SRY-box transcription factor 6

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.